ACP
ETNB

Acuta Capital Partners’s 89bio ETNB Stock Holding History

Acuta Capital Partners’s Portfolio ETNB Stock Details ETNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-32,800
Closed -$506K – 45
2023
Q3 		$506K Buy
+32,800
New +$551K 0.34% 37
2021
Q2 		– Sell
-393,548
Closed -$9.32M – 42
2021
Q1 		$9.32M Sell
393,548
-40,852
-9% -$943K 3.36% 6
2020
Q4 		$10.6M Buy
434,400
+16,900
+4% +$432K 2.88% 12
2020
Q3 		$10.7M Buy
+417,500
New +$13.2M 2.91% 11

Other funds holding ETNB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Acuta Capital Partners's ETNB Position: Q4 2023 in Review

Acuta Capital Partners sold out of 89bio (ETNB) in Q4 2023, closing a stake of 32,800 shares — an estimated $506K sold.

Acuta Capital Partners first reported a position in ETNB in Q3 2020 and held it in 4 quarters. The position peaked at $10.7M in Q3 2020. 153 funds tracked by Wall St. Rank hold ETNB as of Q4 2023.

  • Acuta Capital Partners reported no remaining 89bio position as of Q4 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 32,800 89bio shares in Q4 2023, an estimated $506K.
  • Acuta Capital Partners first reported a position in 89bio in Q3 2020 and held it in 4 quarters.
  • Acuta Capital Partners's 89bio position peaked at $10.7M in Q3 2020.
  • 153 funds tracked by Wall St. Rank held 89bio as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.